Loading stock data...

Beryl Drugs Limited

BSE: BERLDRG

BSE
24.50 0.20 (0.82%)

Prev Close

24.3

Open Price

24.85

Volume

2,367

Today Low / High

23.75 / 25.2

52 WK Low / High

17.35 / 43.7

Range

23 - 26

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 24.5, reflecting a change of 0.2 (0.82305%). The expected target range on the BSE is 23 - 26. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

04 Sep 25.99 -5.93%
03 Sep 25.50 -5.49%
02 Sep 27.49 -8.84%
01 Sep 25.99 1.96%
29 Aug 29.00 -13.03%
28 Aug 26.99 4.08%
26 Aug 26.50 -4.34%
25 Aug 22.47 1.29%
22 Aug 21.50 2.47%
21 Aug 22.90 -6.11%
20 Aug 21.72 2.67%
19 Aug 20.60 5.44%

Beryl Drugs Limited Graph

Beryl Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Beryl Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 24.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 24.50 24.75 22.27 - 27.22
24.99 19.99 - 29.99
25.24 17.66 - 32.81
Bearish Scenario 24.50 24.26 21.83 - 26.68
24.01 19.21 - 28.81
23.77 16.64 - 30.89

Overview of Beryl Drugs Limited

ISIN

INE415H01017

Industry

Medical - Pharmaceuticals

Vol.Avg

2,896

Market Cap

124,003,065

Last Dividend

0

Official Website

Visit Website

IPO Date

2005-06-14

DCF Diff

N/A

DCF

0

Financial Ratios Every Investor Needs

Stock Rating Details for BERLDRG

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 22.55 Cr 14.24 Cr 8.31 Cr 0.3686 0.00 Cr 0.00 Cr 1.40 Cr 0.58 Cr 1.14 2.64 Cr 0.0257
2024-03-31 26.45 Cr 17.77 Cr 8.68 Cr 0.3283 0.00 Cr 0.37 Cr 1.18 Cr 0.77 Cr 1.52 2.66 Cr 0.0291
2023-03-31 26.71 Cr 18.58 Cr 8.13 Cr 0.3043 0.00 Cr 0.36 Cr 1.19 Cr 0.77 Cr 1.51 2.23 Cr 0.0287
2022-03-31 14.45 Cr 10.44 Cr 4.02 Cr 0.2780 0.00 Cr 0.34 Cr -0.65 Cr -0.66 Cr -1.30 0.56 Cr -0.0456
2021-03-31 13.84 Cr 9.46 Cr 4.39 Cr 0.3168 0.00 Cr 0.44 Cr 0.20 Cr 0.24 Cr 0.47 2.07 Cr 0.0173

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.81 Cr 15.96 Cr 6.46 Cr 9.5038 Cr 4.07 Cr 3.26 Cr 1.90 Cr 6.00 Cr 0.00 Cr 0.00 Cr 0.43 Cr 4.3000 Cr
2024-03-31 0.12 Cr 17.49 Cr 8.56 Cr 8.9233 Cr 5.09 Cr 4.97 Cr 1.81 Cr 5.96 Cr 0.18 Cr 0.00 Cr 0.33 Cr 5.7554 Cr
2023-03-31 0.28 Cr 17.51 Cr 9.45 Cr 8.0664 Cr 4.54 Cr 4.26 Cr 1.05 Cr 5.81 Cr 0.13 Cr 0.11 Cr 0.37 Cr 6.3289 Cr
2022-03-31 0.27 Cr 17.82 Cr 10.53 Cr 7.2936 Cr 5.29 Cr 5.02 Cr 2.98 Cr 5.86 Cr 0.19 Cr 0.09 Cr 0.34 Cr 8.4925 Cr
2021-03-31 0.45 Cr 18.65 Cr 10.72 Cr 7.9294 Cr 5.12 Cr 4.67 Cr 2.27 Cr 7.32 Cr 0.10 Cr 0.00 Cr 0.32 Cr 8.2133 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 2.1069 Cr -0.3971 Cr -1.0204 Cr -0.0782 Cr 0.6895 Cr 0.8144 Cr -2.1851 Cr 0.5789 Cr -1.0204 Cr 0.0000 Cr -0.6426 Cr
2024-03-31 0.8202 Cr -1.0817 Cr 0.1032 Cr -0.5314 Cr -0.1582 Cr 0.1249 Cr -1.3516 Cr 1.0097 Cr 0.5668 Cr 0.0000 Cr -0.2055 Cr
2023-03-31 2.4804 Cr -1.3017 Cr -1.1671 Cr 0.9169 Cr 0.0117 Cr 0.2831 Cr -1.5635 Cr 0.9839 Cr -0.7516 Cr 0.0000 Cr 1.9236 Cr
2022-03-31 -0.4688 Cr 0.5240 Cr -0.2359 Cr -0.8843 Cr -0.1807 Cr 0.2714 Cr -0.4155 Cr -0.9503 Cr 0.0017 Cr 0.0000 Cr -0.7092 Cr
2021-03-31 0.3385 Cr 0.2550 Cr -0.5377 Cr -0.7144 Cr 0.0558 Cr 0.4521 Cr -1.0529 Cr 0.3480 Cr -0.1113 Cr 0.0000 Cr -1.1116 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-06-30 4.79 Cr 2.03 Cr 2.77 Cr 0.5776 0.17 Cr 0.02 Cr 0.04 0.55 Cr 0.0044
2025-03-31 5.22 Cr 3.73 Cr 1.49 Cr 0.2857 0.18 Cr 0.15 Cr 0.29 0.50 Cr 0.0291
2024-12-31 5.31 Cr 1.83 Cr 3.48 Cr 0.6546 0.28 Cr 0.05 Cr 0.10 0.59 Cr 0.0098
2024-09-30 5.61 Cr 2.68 Cr 2.93 Cr 0.5225 0.23 Cr 0.01 Cr 0.01 0.57 Cr 0.0012
2024-06-30 6.25 Cr 4.23 Cr 2.02 Cr 0.3230 0.67 Cr 0.37 Cr 0.73 0.99 Cr 0.0589

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 0.81 Cr 0.00 Cr 0.81 Cr 5.46 Cr 1.90 Cr 9.04 Cr 6.00 Cr 15.96 Cr 6.46 Cr
2024-12-31 0.00 Cr 0.00 Cr 0.18 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -9.30 Cr
2024-09-30 0.08 Cr 0.19 Cr 0.27 Cr 7.25 Cr 1.26 Cr 8.96 Cr 7.06 Cr 17.00 Cr 7.70 Cr
2024-06-30 0.00 Cr 0.00 Cr 0.22 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -8.92 Cr
2024-03-31 0.12 Cr 0.10 Cr 0.22 Cr 7.59 Cr 1.81 Cr 10.22 Cr 5.96 Cr 17.49 Cr 8.56 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 0.05 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 0.01 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 0.37 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 -0.35 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 0.31 Cr 0.62 Cr 0.00 Cr 0.00 Cr 0.62 Cr 1.06 Cr 0.44 Cr 0.00 Cr 0.62 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹843.40 ₹100,991,834,050.00 ₹68,509.00

Key Executives

Chief Financial Officer
Mr. Ashish Baraskar

Gender: male

Year Born:

MD & Executive Director
Mr. Sanjay Sethi

Gender: male

Year Born: 1963

Compliance Officer & Company Secretary
Ms. Neha Sharma CS

Gender: female

Year Born:

FAQs about Beryl Drugs Limited

Who is the CEO of the company?

The CEO is Sanjay Sethi.

What is the current market price of the stock?

The current price is ₹24.45.

What is the 52-week price range?

The range is ₹17.35-43.7.

What is the market capitalization of the company?

The market capitalization is ₹12.40 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 55.57.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Beryl Drugs Limited (ISIN: INE415H01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹12.40 crores and an average daily volume of 2,896 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.